Education
About Us
Working with TipRanks
Follow Us
Rani Therapeutics Holdings, Inc. Class A (RANI)
:RANI
RANI Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.39 - $3.75
Previous CloseN/A
Volume228.85K
Average Volume (3M)763.22K
Market Cap
$33.06M
Enterprise Value$26.10M
Total Cash (Recent Filing)$10.22M
Total Debt (Recent Filing)$19.39M
Price to Earnings (P/E)―
Beta0.70
Next Earnings
Nov 12, 2025EPS Estimate
-0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.18
Shares Outstanding47,898,228
10 Day Avg. Volume557,739
30 Day Avg. Volume763,217
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.79
Enterprise Value/Revenue21.75
Enterprise Value/Gross Profit37.24
Enterprise Value/Ebitda-0.54
Forecast
1Y Price Target
$9.00Price Target Upside1856.52% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering0
Bulls Say, Bears Say
Bulls Say
Innovative TechnologyRaniPill delivery demonstrated comparable bioavailability to the subQ route of delivery for both molecules studied.
Market PotentialThe obesity market is massive, with ~70M obese American adults, creating potential for multiple players and the versatility of RaniPill could enable further partnerships or internal development programs as obesity drugs come off-patent.
Strategic PartnershipRani entered into a research agreement with Chugai Pharmaceutical Co., indicating a significant collaboration.
Bears Say
Clinical RisksRisks include, but are not limited to: negative Phase 2 data; negative clinical readouts with other candidates; failure to achieve approvals for key pipeline projects; possible partnership risk; slower-than-projected market uptake.
Financial PerformanceRani Therapeutics reported 1Q25 results with a net loss of ($12.7M) and ended the period with $15.9M in cash, indicating the company will require additional capital in the near term.
Funding RequirementRani disclosed a letter agreement with an existing investor resulting in gross proceeds of $4.3M from warrant exercise, highlighting the need for additional funding.
Rani Therapeutics Holdings News
RANI FAQ
What was Rani Therapeutics Holdings, Inc. Class A’s price range in the past 12 months?
Rani Therapeutics Holdings, Inc. Class A lowest stock price was $0.39 and its highest was $3.75 in the past 12 months.
What is Rani Therapeutics Holdings, Inc. Class A’s market cap?
Rani Therapeutics Holdings, Inc. Class A’s market cap is $33.06M.
When is Rani Therapeutics Holdings, Inc. Class A’s upcoming earnings report date?
Rani Therapeutics Holdings, Inc. Class A’s upcoming earnings report date is Nov 12, 2025 which is in 67 days.
How were Rani Therapeutics Holdings, Inc. Class A’s earnings last quarter?
Rani Therapeutics Holdings, Inc. Class A released its earnings results on Aug 07, 2025. The company reported -$0.18 earnings per share for the quarter, beating the consensus estimate of -$0.285 by $0.105.
Is Rani Therapeutics Holdings, Inc. Class A overvalued?
According to Wall Street analysts Rani Therapeutics Holdings, Inc. Class A’s price is currently Undervalued.
Does Rani Therapeutics Holdings, Inc. Class A pay dividends?
Rani Therapeutics Holdings, Inc. Class A does not currently pay dividends.
What is Rani Therapeutics Holdings, Inc. Class A’s EPS estimate?
Rani Therapeutics Holdings, Inc. Class A’s EPS estimate is -0.11.
How many shares outstanding does Rani Therapeutics Holdings, Inc. Class A have?
Rani Therapeutics Holdings, Inc. Class A has 47,898,228 shares outstanding.
What happened to Rani Therapeutics Holdings, Inc. Class A’s price movement after its last earnings report?
Rani Therapeutics Holdings, Inc. Class A reported an EPS of -$0.18 in its last earnings report, beating expectations of -$0.285. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Rani Therapeutics Holdings, Inc. Class A?
Currently, no hedge funds are holding shares in RANI
Rani Therapeutics Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$9.00 (1856.52% Upside)
$9.00 (1856.52% Upside)
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.6%
Last 30 Days ▼ 4.5%
Last 30 Days ▼ 4.5%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-83.74%
12-Months-Change
Fundamentals
Return on Equity
-1372.59%
Trailing 12-Months
Asset Growth
-61.35%
Trailing 12-Months
Company Description
Rani Therapeutics Holdings, Inc. Class A
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a platform that is intended to replace subcutaneous or IV injection of biologics with oral dosing. Its product pipeline includes RT-101, an octreotide, which has completed Phase I clinical trial for the treatment of neuroendocrine tumors and acromegaly; RT-105, an anti-TNF-alpha antibody to treat psoriatic arthritis; RT-102, a parathyroid hormone that is in preclinical studies for the treatment of osteoporosis; RT-109, a human growth hormone to treat growth hormone deficiency; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-106, a basal insulin for the treatment of type 2 diabetes. The company was incorporated in 2012 and is headquartered in San Jose, California.
Technical Analysis
Corbus Pharmaceuticals
―
Adverum Biotechnologies
―
IGM Biosciences
―
Adagene
―
TScan Therapeutics
―
Ownership Overview
20.34% Insiders
2.09% Mutual Funds
8.85% Other Institutional Investors
66.98% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---